TNF and Cowden disease: In luminal disease, infliximab response rates of up to 90% and remission rates at 1 year of 55%–60% have been reported.40, 41 Infliximab improved outcomes of perianal CD with response rates of 75% and remission rates of 50% at 1 year.42 Adalimumab achieved 1-year remission rates of 45% in anti-TNFα antibody naïve children and 20% in infliximab non-responders.43